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fig. 17 Hospital admissions attributed to haemochromatosis in england from 
1989/1990 to 2002/2003. (a) Age-standardized in-patient admission rate per 
100,000 per year. (b) Age-standardized day-case admission rate per 100,000 
per year.
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Overview
the past 30 years have witnessed major progress 
in the knowledge and management of liver disease, 
yet approximately 29 million people in the european 
Union still suffer from a chronic liver condition. 
difficulties in accessing data from individual countries 
hinder global evaluation of liver disease in europe. 
this report reviews 260 epidemiological studies 
published in the last five years to survey the current 
state of evidence on the burden of liver disease in 
europe and its causes. 
the incidence and prevalence of two conditions, 
cirrhosis and primary liver cancer, are key to 
understanding the burden of liver disease. they 
represent the end-stage of liver pathology and thus 
are indicative of the associated mortality. literature 
on the prevalence and incidence of cirrhosis is 
scarce. However, available data suggest that 
about 0.1% of the european population is affected 
by cirrhosis, corresponding to 14-26 new cases 
per 100,000 inhabitants per year or an estimated 
170,000 deaths per year [2]. there are, however, 
large intra-european variations. About 0.1% of 
Hungarian males will die of cirrhosis every year 
compared with 0.001% of greek females. 
Hepatocellular carcinoma (constituting 70-90% 
of cases of primary liver cancer) is the fifth most 
common cause of cancer in europe and one of 
the most serious outcomes of cirrhosis. european 
epidemiological data show that there are 1-13 new 
cases of hepatocellular carcinoma and 1-10 deaths 
per 100,000 inhabitants per year. wHo estimate 
that liver cancer is responsible for around 47,000 
deaths per year in the eU.
the four leading causes of cirrhosis and primary liver 
cancer in europe are harmful alcohol consumption, 
viral hepatitis b and c and metabolic syndromes 
related to overweight and obesity.  
chronic alcohol consumption is the main cause 
of cirrhosis in europe. Alcohol consumption 
decreased in the 1990s, but has increased again in 
the last decade to stabilize at a high level of >9 litres 
of pure alcohol per year on average, although there 
are large variations among european countries.  
chronic viral hepatitis b is the second major cause 
of both cirrhosis and liver cancer. between 0.5% 
and 0.7% of the european population is affected 
by chronic hepatitis b, with the highest prevalence 
being recorded in romania (5.6%) and greece 
(3.4%). by comparison, Hiv prevalence is only 
0.2% (Hiv is 50-100 times less infectious). the 
availability of a vaccine has resulted in a decrease 
in the prevalence of Hbv, although it remains 
responsible for 30% of cases of cirrhosis and 15% 
of cases of primary liver cancer. 
chronic hepatitis c is an important risk factor for 
hepatocellular carcinoma, which develops several 
decades after infection. since the discovery of 
the virus in the late eighties, the number of new 
cases of infection has dropped substantially. 
prevalence rates of hepatitis c virus (Hcv) infection 
in the last decade in the european population were 
between 0.13 and 3.26%, the highest rates being 
found in italy and romania. these Hcv-infected 
populations will develop complications in the years 
to come, leading to a substantial increase in the 
burden of disease. it is of great concern that about 
90% of people in europe infected by viral hepatitis 
are unaware of their status.
Non-alcoholic fatty liver disease (NAfld) is 
becoming a major concern with the increasing 
incidence of obesity in europe. in this condition, 
accumulation of fat in the liver leads to chronic liver 
disease. Available data suggest the prevalence 
rate of NAfld is 2–44% in the general european 
population (including obese children) and 42.6–
69.5% in people with type 2 diabetes. NAfld 
increases the risk of cirrhosis and liver cancer.
each of these four major causes of liver disease 
is amenable to prevention and treatment, reducing 
the burden of liver disease in europe and saving 
lives. However, epidemiological data are scarce. 
Additional surveys are urgently needed to provide 
reliable information, without which it will not be 
possible to implement cost-effective prevention 
programmes and novel treatments to tackle liver 
disease and avoidable deaths in europe.
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the past 30 years have witnessed major 
progress in the knowledge and management of 
liver disease yet approximately 29 million persons 
in the european Union still suffer from a chronic 
liver condition. difficulties in accessing data 
from individual countries hinder comprehensive 
evaluation of the burden of liver disease in europe 
and comparison with other diseases. moreover, 
very few reviews have studied both chronic 
liver conditions, such as cirrhosis and cancer, 
and their major causes, such as viral hepatitis, 
alcohol intake and metabolic syndrome.  it is 
likely that the causes of chronic liver diseases 
differ from country to country but no reliable data 
exist about this.  A large systematic review of 
all epidemiological data available for european 
countries has hitherto not been undertaken. 
Here we review evidence of the burden and 
causes of liver disease in europe, drawing on a 
survey of all epidemiological data published over 
the course of the last five years.
iNTrOdUCTiON
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medliNe, embAse, and the cochrane library 
were searched for relevant articles using the 
following medical subject headings (mesH) 
terms  ‘liver’ and [‘disease’ or ‘epidemiology’]. 
the search encompassed articles published 
throughout the last five years in any european 
language. studies were included if: (1) they 
presented epidemiological data; (2) they included 
patients who lived in the european Union (eU27) 
or Norway (but not necessarily exclusively so); (3) 
they were published or accepted for publication 
as full-length articles. studies were excluded if: 
(1) they estimated prevalence or incidence from 
data collected before 1995; (2) they studied very 
specific populations; (3) they were published 
only in abstract form so that the methodological 
quality could not be assessed. when the results 
of a single study were reported in more than one 
publication, only the most recent and complete 
data were included in the systematic review.
A manual search of references cited in retrieved 
articles was also conducted to identify studies 
not found in the database search. data presented 
in world Health organization (wHo) reports, in 
european centre for disease prevention and 
control (ecdc) reports and on eUroHep.Net 
were also included.
All available data on liver disease incidence and 
prevalence and on associated mortality and 
trends were extracted from the reviewed articles. 
most mortality statistics were derived from official 
causes of death recorded on death certificates. 
of 4,256 reviewed studies, 260 met the inclusion 
criteria.
the european liver transplant registry (eltr) 
was used to describe the epidemiology of liver 
transplantation in europe as it represents more 
than 95% of all official published european data 
(fig. 5, page 16).
geographical factors necessitate caution in 
the interpretation of parts of this review for two 
reasons: (1) inter-country variation in death-
reporting processes; therefore caution must be 
exercised when making comparisons between 
countries; (2) the definition of the european zone 
varies according to the source, so care must 
be taken when assessing data reported at the 
european level. According to wHo, european 
countries include all eastern and central european 
countries as well as the russian federation. by 
contrast, data given for the eU27 refer only to 
countries that belong to the european Union. 
MeTHOds
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According to wHo, liver cirrhosis accounted 
for 1.8% of all deaths in europe (using wHo’s 
wide geographical definition), causing around 
170,000 deaths per year.  in the last decades of 
the 20th century, a very strong east-west gradient 
in mortality rates was observed, with the level of 
liver cirrhosis mortality in south-eastern europe 
(especially in Hungary and moldova but also in 
slovakia, slovenia and romania) and in north-
eastern european countries achieving rates never 
before seen in europe [1, 2] (figs. 1 and 2, see page 
9 and 11). However, in recent years, liver cirrhosis 
has also become a serious health threat in some 
western european countries, such as the United 
Kingdom and ireland, where over the last 10 years 
the associated mortality has increased.
Alcohol has long been identified as the strongest 
risk factor for liver cirrhosis [3, 4]. in fact, cirrhosis 
mortality has traditionally been used as a valid 
indicator for tracing the health consequences of 
alcohol abuse. However, infections by the hepatitis 
b and c viruses (Hbv and Hcv) are also important 
determinants of cirrhosis, and their possible 
contribution to temporal trends should be taken 
into account. Zatonski et al. studied the temporal 
trends of liver cirrhosis in european countries, 
based on the wHo mortality database (http://data.
euro.who.int) [2]. radical increases in liver cirrhosis 
mortalities were observed from the 1970’s within a 
group of several south-eastern european countries. 
Hungary was an especially dramatic example. 
from the mid-1970’s to the mid-1990’s, cirrhosis 
mortality rates in Hungary increased from 20 to 148 
per 100,000 males (the highest level ever registered 
in any european country) and from about 8 to 48 
per 100,000 females [2]. by 2002 these rates had 
slightly declined to 103 per 100,000 males and 32 
per 100,000 females [2].  Another group of countries 
in which dramatic changes were observed were the 
North-eastern european countries (former soviet 
Union countries such as estonia, latvia, lithuania 
and poland). for the reasons already stated, it is 
difficult to compare mortality rates from one country 
to another, but the trends are unmistakable. in 
contrast, in the mediterranean region (france, italy, 
spain, portugal and greece) appreciable declines 
in cirrhosis mortality were observed in populations 
that historically had the highest cirrhosis mortality 
levels in both sexes. Hbv vaccine, reduced alcohol 
consumption and reduction of Hcv transmission 
have probably contributed to this decrease. A recent 
french study might appear to buck this trend, finding 
0.3% of screened males aged more than 40 years 
old to have liver cirrhosis [5]. However, these results 
should be interpreted with caution as the subjects 
were seen within a free screening programme and 
therefore were potentially at high risk of liver fibrosis 
[5]. the associated causes of liver disease in this 
study were a combination of alcoholic and NAfld 
(66%), NAfld only (13%), alcohol (9%), Hcv 
(6%), and other causal factors (6%) [5]. factors 
independently associated with fibrosis were age, 
male gender, waist circumference, presence of 
Hcv antibody and alcohol consumption [5]. these 
results suggest that alcohol and NAfld are two 
causal factors with the potential to keep levels of 
liver cirrhosis relatively high in western european 
countries.
Among north european countries, there was 
about a two-fold increase in cirrhosis rates in the 
UK and ireland until the 1990s, according to the 
wHo mortality database [2]. this is confirmed by a 
study based on the UK general practice research 
database (gprd), where the prevalence of liver 
cirrhosis increased by almost 50% between 1992 
and 2001 to 76.3 per 100,000 persons (table 1, 
page 10) [6]. in another UK study, the incidence rate 
of cirrhosis was 26 per 100,000 women between 
1996 and 2005 [7]. in a nationwide, population-
based registry study in denmark, liver cirrhosis 
CirrHOsis
resUlTs
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prevalence remained high between 1996 and 2005 
[8]. in 2005, the alcoholic cirrhosis incidence rates 
were 26.5 (25.7-17.4) and 11.8 (11.2-12.4) per 
100,000 per year for men and women, respectively, 
and the prevalence rates were 132.6 (130.7-134.5) 
and 70.1 (68.8-71.5) per 100,000 for men and 
women, respectively. in sweden, liver cirrhosis 
incidence was close to that of denmark, estimated 
at 15.3 ± 2.4 per 100,000 inhabitants, and did not 
decrease between 1996 and 2005 [9].
in summary, liver cirrhosis is responsible for 
1-2% of all deaths in most european countries 
according to the wHo database. increasing or 
stable incidences of the disease were reported 
in the published studies (table 1, page 10). in 
mediterranean countries, alcohol consumption and 
the obesity epidemic threaten to halt the recently-
improving trend in liver cirrhosis prevalence, or 
even to reverse it. Amongst northern european 
countries such as denmark and sweden, liver 
cirrhosis prevalence has not decreased and still 
represents a non-negligible factor of morbidity and 
mortality.  finally, in the UK and ireland, all studies 
agreed on the worrying increase in the incidence of 
liver cirrhosis. 
Fig. 1 – Liver cirrhosis mortality in Mediterranean countries 
and in Hungary, males 20-64 years, WHO [2].
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Country author study years and 
population
diagnosis prevalence or 
incidence rates  
(95% Ci)
Trends in prevalence 
or incidence rates
denmark jepsen [8] 1988-2005; alcoholic 
cirrhosis: a nationwide 
population-based, hospital 
registry study
Histology in 2001–2005, the 
alcoholic cirrhosis 
incidence rates were 
22.5 (25.7-17.4) and 
11.8 (11.2-12.4) per 
100,000 per year for 
men and women, 
respectively, and the 
prevalence rates were 
132.6 (130.7-134.5) 
and 70.1 (68.8-71.5) 
per 100,000
the alcoholic cirrhosis 
prevalence and 
incidence rates for men 
and women of any 
age did not change 
significantly from 1996 
to 2005
france poynard [5] 2006-2008; 7,463 
consecutive subjects aged 
40 years or older, seen for 
a free voluntary screening 
program in two french 
social security health 
examination centres, 95% 
male
Histology the estimated 
prevalence of fibrosis 
was 1.3% (1.1%-1.7%) 
and of cirrhosis was 
0.3% (0.2%-0.5%)
sweden gunnarsdottir [9] 1994-2003; all patients 
diagnosed with liver 
cirrhosis in gothenburg 
(600,000 inhabitants) 
Histology the mean annual 
incidence rate per 
100,000 inhabitants 
in sweden was 15.3 
(± 2.4)
the incidence rate 
and the proportion of 
alcohol aetiology were 
fairly constant over the 
study period
UK fleming [6] 1992-2001; the UK 
general practice research 
database (gprd), 
persons aged 25 and 
over, 58% male
Any diagnostic 
or therapeutic 
code for 
cirrhosis, 
oesophageal 
varices or portal 
hypertension
crude incidence was 
14.55 per 100,000 
person years. 
prevalence of cirrhosis 
was an estimated 76.3 
per 100,000 population 
aged over 25 in mid-
2001
the cirrhosis incidence 
increased from 12.05 
to 16.99 per 100,000 
person years from 
1992 to 2001
UK liu [7] 1996-2005; the million 
women study (an on-
going prospective study 
of 1.3 million United 
Kingdom women aged 50 
and over)
icd-10 
diagnosis code 
K70, K73, or 
K74
After a mean follow-up 
of 6.1 years (1996-
2005), incidence rate 
of cirrhosis was 26 per 
100,000 per person-
years in women
 
Table 1 – European studies assessing the prevalence or 
incidence of liver cirrhosis.
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Fig. 2 – Age-standardized death rates per 100,000 
population from liver cirrhosis in European countries, 
males and females aged 20–64; WHO Mortality
Database 2000-2002 [2].
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Hepatocellular carcinoma (Hcc), accounts for 
70–90% of primary liver cancers (plc). without 
any treatment, Hcc is rapidly fatal, with a 5-year 
survival rate of around 5%. when liver resection 
with curative intention is performed, 5-year 
survival rates reach 26-40% in french studies [10, 
11].  the management of Hcc is complicated by 
the presence of liver cirrhosis in more than 80% of 
patients.  liver cirrhosis is often the direct cause of 
death and may hinder cancer treatment. over half 
a million new cases of Hcc are diagnosed each 
year worldwide [12-14].  in recent years decreasing 
incidence has been reported in some high 
incidence countries, while significant increases 
have been reported in several low incidence 
countries [12, 15, 16]. these trends coincide with 
changes in the consumption of alcohol and the 
prevalence of Hbv or Hcv infection, which are 
major risk factors for Hcc [12]. cancer registry 
data must be preferred for survey purposes as 
it is not selective, reporting data for virtually all 
primary liver cancers. by contrast, clinical studies 
adopt rigorous selection criteria and are typically 
performed by tertiary referral hospitals that are 
likely to be centres of excellence. clinical studies 
may provide indications as to the best outcomes 
possible and usually show better survival than 
registry data.
thanks to the globocAN project (http://
globocan.iarc.fr), we have estimates of liver 
cancer incidence rates for each eU27 country. 
globocAN is a project led by the wHo and 
provides estimates of national rates of incidence, 
mortality and prevalence for every country in 
the world, based on national population-based 
cancer registries and death registration systems. 
globocAN 2008 took into account delays in the 
availability of data by computing predictions of 
national incidence and mortality rates to the year 
2008, wherever possible. 
these calculations were based on published data 
where available or were estimated from national 
mortality and incidence data or from mortality 
data provided by local cancer registries. recent 
incidence data (up to 2007) were extracted 
by globocAN from reports available on the 
internet from the national cancer registries in 
Austria, belgium, bulgaria, croatia, cyprus, 
czech republic, ireland, luxembourg, malta, 
the Netherlands, slovakia, slovenia and Ukraine. 
data for the five Nordic countries, denmark, 
finland, iceland, Norway and sweden, were 
obtained from the NordcAN database of the 
Association of the Nordic cancer registries. in 
the United Kingdom, historical incidence data 
were available for the populations of england, 
scotland and wales. Additional historical national 
incidence data for belarus, estonia, latvia and 
lithuania, together with local incidence data used 
for modelling purposes, were extracted from the 
‘cancer incidence in five continents’ series of 
monographs published by wHo.
in the eU27 in 2008, liver cancer incidence was 
10.6 and 3.6 per 100,000 persons for men and 
women, respectively [17]. for men, the highest 
incidence was in italy (19.9 and 6.8 per 100,000 
persons for men and women, respectively) and 
the lowest was in the Netherlands (2.8 and 1.1 
per 100,000 persons for men and for women, 
respectively) [17]. As expected, estimated 
mortality rates were very close to incidence rates, 
indeed the two measures were exactly the same 
for the eU27 overall [17]. complete results for all 
eU27 countries are given on figs. 3 and 4, page 15.
primAry liver CaNCer
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few european studies have investigated the 
incidence of plc. those that have were all 
based on local or national registries (table 2, 
page 14). in a study based on three danish 
registries, the incidence rate of plc between 
1985 and 2003 was 5.9 (95% ci 5.4–6.3) and 
3.7 (95% ci 3.4–4.0) per 100,000 person-years 
in men and in women, respectively [18]. in the 
same study, the standardized incidence rate 
of plc increased from 3.2 (95% ci 2.2–4.2) to 
5.0 (95% ci 3.8–6.2) per 100,000 person-years 
between 1985 and 2003 [18]. these results were 
consistent with data from globocAN which 
found incidence rates for denmark in 2008 of 
5.8 and 1.9 per 100,000 persons for men and 
for women, respectively [17]. three studies 
published for france estimated plc incidence 
rates during the 1990’s to be between 9.5 and 
13.8 for men and between 0.8 and 1.7 for women 
[19-21]. globocAN found similar rates, with 
10.5 and 2.2 per 100,000 persons for men and 
for women, respectively [17]. finally, in an italian 
study based on 20 local registries, the overall 
standardized incidence rate of plc was 21.1 per 
100,000 person-years in men and 6.0 in women 
[22]. rates varied widely among different regions 
and the results were consistent with those from 
globocAN [17].
in summary, plc rates exceed 10 per 100,000 
inhabitants in southern european countries, 
reaching 13 per 100,000 in italy and greece. it is 
also common in germany and eastern european 
countries, with incidence rates of 5-10 per 
100,000 inhabitants. Unlike other cancers, the 
mortality rate is very close to the incidence rate 
because of the very low associated survival rate. 
thus, liver cancer is responsible for many deaths 
in europe, around 47,000 per annum according 
to the wHo mortality database. this is lower than 
the rate for cirrhosis-related mortality (table 13, 
page 46).
 
is the number of deaths in europe caused 
each year by liver cancer according to the 
wHo mortality database.
~ 47,000
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Country author study year(s) and 
population
diagnosis standardized incidence 
rates per 100,000 
person-years
Trends in incidence 
rates
eU27 ferlay [17], 
globocAN
2008; local cancer 
registries
Histology or clinical 
and imaging findings
10.6 in men, 3.6 in 
women
denmark erichsen [18] 1985-2004; the three 
danish counties of North 
jutland, Aarhus and 
viborg
Histology or clinical 
and imaging findings
5.9 (95% ci 5.4–6.3) in 
men, 3.7 (95% ci 3.4–4.0) 
in women in 1985–2003
increased from 3.2 
(95% ci 2.2-4.2) to 
5.0 (95% ci 3.8-6.2) 
from 1985 to 2003
france borie [20] 1997-1998; 9 regional 
french registries 
Histology or clinical 
and imaging findings
9.5 in men, 1.7 in women
france caumes [21] 2002-2003; the finistère 
cancer registry
Histology or clinical 
and imaging findings
13.8 in men, 0.8 in 
women
france binder-
foucard [19]
1990-1999; the cancer 
registry of bas-rhin 
Histology or clinical 
and imaging findings
11.7 in men, 1.5 in 
women
No incidence trend 
for men or women 
(p=0.75)
italy dal maso [22] 1998-2002; 20 italian 
cancer registries 
Histology or clinical 
and imaging findings
21.1 in men, 6.0 in 
women. 
in Naples, the world-
standardized incidence 
rates for persons aged 
0–79 were 29.5 and 8.3 
per 100,000 in men and 
women, respectively, 
approaching those found 
in highest risk areas of 
Asia.
the change in 
annual incidence rate 
between 1988 and 
2002 was 0.8% in 
men (95% ci 0.5-
2.1%) and 1.1% 
in women (95% ci 
0.2-2.1%).
 
Table 2 – European studies assessing incidence 
of primary liver cancer.
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Fig. 4 – Estimated age-standardized mortality rates per 100,000 
for liver cancer in 2008; WHO, GLOBOCAN, 2008.
Fig. 3 – Estimated age-standardized incidence rates of liver 
cancer per 100,000 in 2008; WHO, GLOBOCAN, 2008.
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15,714
16,366
13,684
663
4,318
1,972
734
801
12
14,116
1,645
1,089
2,193 425
11,697
1,645
liver TraNsplaNTaTiON
Fig. 5 – Number of liver transplantations in European countries, 
May 1968 to December 2009; ELTR [23].
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more than 5,500 orthotopic liver transplantations 
(olts) are currently performed in europe per year 
[23]. figure 5, on page 16, shows the number of 
olts that were performed in 16 european countries 
between 1968 and 2009. After rapid growth in the 
1980s and 1990s, the annual number of olts has 
stopped growing over the last 10 years, limited 
by the availability of organs (fig. 6, below). donor 
shortage currently represents the most important 
limiting factor for olts [24, 25] and alternatives 
to standard cadaveric olts (a liver from someone 
that has died), such as split (one liver is divided for 
two recipients), domino (the original liver from a 
transplantation patient is transplanted into someone 
else), or living related (a portion of a healthy person’s 
liver is used) olts are increasingly used, accounting 
for 11% of all procedures [26, 27]. in general, olts 
are considered for any patient with chronic liver 
disease that leads to life-threatening complications 
and a survival prognosis of one year or less. the 
main indications for liver transplantation in europe 
are cirrhosis and tumours, mainly related to viruses 
and alcohol (figs. 7 and 8, page 18).
liver transplantation for malignant diseases is 
feasible, resulting in excellent outcomes in selected 
patients, and comprises 14% of all liver transplants 
in the eltr [23]. it is currently a treatment option for 
patients with primary carcinomas of the liver, Hcc 
representing 84% of olts for cancer. other types of 
primary liver carcinomas eligible for transplantation 
include cholangiocarcinoma, hepatoblastoma, 
and hemangioendothelioma. the most common 
secondary carcinomas that are considered for 
olt include metastases from carcinoid tumours, 
neuroendocrine tumours and gastrinomas [28, 29]. 
reduced liver, split liver, living donor and domino 
transplants have been used increasingly in recent 
years as alternatives to full-size olt procedures. 
one of the most important findings in the evolution 
of olts is the significant improvement in results 
with time. currently the 1-year survival rate is 
reported to be 83% (all indications considered). 
this improvement is probably due to greater 
technical expertise, better selection of patients, and 
improved post-olt management of complications 
and immunosuppressive therapy. 
Fig. 6 –  Growth in the annual numbers of liver transplants in Europe. 
* The decrease in 2009 is due to the absence of updated figures from some centres.
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Metabolic diseases 6%
Virus related 40%
Autoimmune 40%
Alcohol 33%
Alcohol + Virus 5%
Budd Chiari 0.8%
Parasitic diseases 0.08%
Acute hepatic failure 8%
Secondary biliary cirrhosis 1%
Primary biliary cirrhosis 10%
Benign liver tumors or Polycystic disease 8%
Cholestatic diseases 10%
Cancers 14%
Cirrhosis 59%
Unknown 7%
Metabolic diseases 6%
Virus related 40%
Autoimmune 40%
Alcohol 33%
Alcohol + Virus 5%
Budd Chiari 0.8%
Parasitic diseases 0.08%
Acute hepatic failure 8%
Secondary biliary cirrhosis 1%
Primary biliary cirrhosis 10%
Benign liver tumors or Polycystic disease 8%
Cholestatic diseases 10%
Cancers 14%
Cirrhosis 59%
Unknown 7%
Fig. 7 – Primary liver diseases leading to liver transplantation in 
Europe, January 1988 to December 2009.
Fig. 8 – Primary indications for liver transplantation in Europe among 
patients with cirrhosis, January 1988 to December 2009.
THe bUrdeN OF liver disease iN eUrOpe – A review of AvAilAble epidemiologicAl dAtA 19
europe is the heaviest drinking region in the world 
in terms of the prevalence of alcohol consumption, 
according to the wHo report ’european status 
report on Alcohol and Health 2010’ [30]. over 20% 
of the european population aged ≥15 reported 
heavy episodic drinking (defined as five or more 
drinks on one occasion, or 50g alcohol) at least 
once a week [30].
Alcohol is the main cause of liver disease, including 
liver cirrhosis (see section on cirrhosis, page 8). 
the mortality rate associated with cirrhosis has 
traditionally been considered a good indicator of 
alcohol-related mortality [2]. cirrhosis can lead to 
Hcc. in france, excessive alcohol consumption is 
responsible for 69% of the cases of plc, making 
it the main risk factor, although viral aetiology is 
increasing [20]. An increase in alcohol-related 
cirrhosis has been observed in estonia [31] and 
in denmark [32] in the last decade, in line with 
increases in alcohol consumption in the 1990s in 
those countries.
standardized mortality rates for alcohol-related 
liver diseases among men and women during 
2000-2005 are available for 24 european countries, 
based on death certificates (fig. 9, below and fig. 
10, page 20). they show a significant impact of 
chronic alcohol consumption on health in europe, 
though the figures vary greatly between countries, 
ranging from 3 per 100,000 men in latvia to more 
than 47 per 100,000 men in Hungary. However, this 
data needs to be interpreted cautiously as there is 
variability between countries in the way mortality 
is declared and how alcohol related diseases 
are recorded in death certificates. Nevertheless, 
when considering alcohol consumption (fig. 11, 
page 20) and alcohol related mortality (figs. 9 and 
10) simultaneously, countries on the lower end 
of both figures (e.g. Norway or sweden) give an 
indication of what could be achieved in terms of 
mortality reduction should proper alcohol policies 
be implemented.
alCOHOl ANd liver disease
Fig. 9 – Mortality from alcohol-related liver diseases among men 
in European countries in 2005; WHO 2010 [30].
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Fig. 11 – Alcohol consumption in Europe in 2005: WHO.
Fig. 10 – Mortality from alcohol-related liver diseases among women in 
European countries in 2005, WHO 2010.
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data on the acute consequences of alcohol 
consumption are scarce. from 1999 to 2008, the 
annual incidence rate of alcoholic hepatitis in the 
danish population rose from 37 to 46 per 100,000 
for men and from 24 to 34 per 100,000 for women, 
according to an epidemiological study of a national 
cohort. the 5-year mortality was 47% without 
cirrhosis, 69% with cirrhosis and 56% overall [33].
trends in alcohol consumption over the last two 
decades, estimated from surveys in each member 
state as well as from alcohol industry statistics, 
showed a decrease during the 1990s. 
this was followed by an increase and stabilization 
at a higher level between 2004 and 2006 (fig. 
12, below). there are huge variations in alcohol 
consumption among european countries (fig. 11, 
page 20). the burden of liver disease attributable to 
the use of alcohol is significant compared to other 
aetiologies. moreover, in many countries alcohol 
consumption causes substantial health, social and 
economic burdens, not only in relation to public 
health problems including liver and psychiatric 
disease but also in terms of accidents and alcohol-
related violence.
Fig. 12 – Alcohol consumption in Europe between 1990 
and 2006; WHO 2010 [30].
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Hepatitis A is caused by infection with the hepatitis 
A virus (HAv). it has an incubation period of 
approximately 28 days and is primarily transmitted 
by the faecal-oral route, either by person-to-person 
contact or consumption of contaminated food 
or water. HAv infection does not result in chronic 
infection or chronic liver disease. manifestations of 
infection vary with age. most infected adults have a 
symptomatic form whereas most infections in children 
are asymptomatic or unrecognized. About 0.5 % of 
cases of hepatitis A will result in acute liver failure and 
death, but mortality reaches up to 2.1% in adults over 
40. HAv antibodies persist for many years after the 
infection has resolved, providing long term immunity 
[34]. HAv vaccines are available today and are 
routinely used in european countries for populations 
and travellers at risk. the picture of HAv epidemiology 
has changed in europe over past decades because 
of improvements in hygiene and sanitation, coupled 
with economic and social advancement. most 
european countries have observed a dramatic drop 
in the level of hepatitis A incidence, and a shift in the 
age-specific seroprevalence rates (table 3, page 23 
and table 4, page 24). As a consequence, a smaller 
fraction of the population is immune, especially early 
in life when HAv infection is mainly asymptomatic. 
the yearly incidence rate of hepatitis A in europe 
today is between 0.55 and 1.5 cases per 100,000 
inhabitants, based on data from epidemiological 
surveillance systems (table 3) and there are 
large differences between european countries. 
Hospitalization rates for HAv infection range from 0.2 
per 100,000 inhabitants in the Netherlands to 94 per 
100,000 in romania (fig. 13, below).
HepaTiTis A
Fig. 13 – Hospitalisation for hepatitis A, incidence per 
100,000 inhabitants in Europe; EUROHEP.NET.
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declining HAv incidence and seroprevalence have 
delayed the age at which individuals become 
infected until adulthood, at which time the 
likelihood of developing the symptomatic illness 
is considerably higher. several countries have 
considered systematic vaccination because of 
the greater disease burden of late HAv infections. 
these vaccination programs have shown to be 
effective in reducing incidence, outbreaks, mortality 
rates and hospitalisation [35]. one strategy is 
to combine HAv and hepatitis b virus (Hbv) 
vaccination. cost-effective analyses performed in 
ireland showed vaccination to be the strategy of 
choice where HAv immunity is 45% or less [36]. 
HAv still poses a serious threat to public health 
in europe, despite declining incidence, because 
reduced population protection leads to more 
symptomatic cases and to outbreaks. epidemics 
were responsible for a 10-fold increase in the 
incidence rate in the czech republic in 2008 [37, 
38] and an incidence rate of 124 per 100,000 
inhabitants in latvia in 2008 [39]. two epidemics 
reported in finland in 1994-1995 and 2002-2003 
started with intravenous drug users and spread to 
the rest of the population [40]. luyten et al. have 
estimated that a HAv outbreak can have a major 
economic impact, ranging from Usd 3,824 to Usd 
200,480 per case [41].
Country author study year(s) and 
population
Case 
identification
incidence 
rates 
per 100,000
Trends in incidence 
rates
czech republic fabianova [38] 2003-2007; general 
population
mandatory case 
declaration
1.48
italy tosti [42] 2006; general population epidemiological 
surveillance system
1.4 decreased from 4.0 
in 1991
Netherlands suijkerbuijk [43] 2005; general population mandatory case 
declaration
1.3 decreased from 6.5 
in 1995
poland baumann [44] 2007; general population mandatory case 
declaration
0.09 A decrease of 31% 
compared to 2006 
(part of a downward 
trend since 1997)
poland baumann [45] 2008; general population mandatory case 
declaration
0.55 increased from 0.09 
in 2007
spain Arteaga [46, 47] 2008; general population Hospitalisation 1.36 decreased from 1.87 
in 2005
Table 3 –  Incidence rates of HAV infection in Europe.
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Country author study year(s) and 
population
diagnostic method prevalence rates 
(95% Ci)
Trends in 
prevalence rates
belgium Quoilion [48] 2007; general population oral (saliva) testing for 
antibodies
20.2% (19.43 – 
21.08) weighted 
for age 
finland broman [40] 1990-2007; patient sample oral (saliva) testing for 
antibodies
30-45%*
greece Kyrka [49] 2008; unvaccinated children 
0-14 years old
oral (saliva) testing for 
antibodies
17.1% 
italy d’Amelio [50] 2005; military recruits oral (saliva) testing for 
antibodies
5.3% decreased from 
66.3% in 1981 to 
29.4% in 1990
*finland has a HAv vaccination program
Table 4 – Prevalence rates of HAV infection in Europe.
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Hepatitis b is caused by infection with the hepatitis 
b virus (Hbv). primary risk factors for Hbv 
transmission are sexual contact, percutaneous 
exposure to infectious body fluids, perinatal 
exposure to an infected mother and prolonged close 
personal contact with an infected person [51]. Acute 
Hbv infection is symptomatic in 30-50% of adults 
over 5 years, with a case-fatality of approximately 
1% [52]. the risk of Hbv infection becoming chronic 
is 90% for infants, 30% for infected children aged 
<5 years and 2-6% for adults [53]. chronic Hbv 
infection is rarely symptomatic in adults. Hbv has 
sometimes been called ‘the silent killer’ because 
infected adults often remain undiagnosed and thus 
untreated until it is too late. throughout europe, an 
average of only 23% of patients knew of hepatitis 
b at the time of their diagnosis and only 27% 
knew they were at risk of contracting it [54]. in a 
french study of Hbv infection, 18% of identified 
patients were detected by standard testing during 
pregnancy [55]. Universal (targeting specific age-
cohorts) vaccination strategies deployed in many 
european countries have achieved high coverage 
rates among infants and adolescents [56].
the yearly incidence of new cases of Hbv shows 
large variation from 0.2 to 11.2 cases per 100,000 
inhabitants in france and iceland, respectively (fig. 
14, page 26).
the prevalence of chronically Hbv-infected patients 
has been estimated from hepatitis b surface 
antigen (HbsAg) identification in sera collected 
from the general population in several european 
countries (table 5, page 26). prevalence estimates 
range from 0.1 to 0.7%, with the exception of 
romania (5.6%) and greece (3.4%) (table 5 and 
table 7, pages 26 and 27).
chronic Hbv infections translate into a heavy 
disease burden in europe. cirrhosis occurs in 20 to 
30% of infected patients [55, 57] with about 25% 
at risk of developing hepatocellular carcinoma, 
thus Hbv is responsible for 10-15% of primary 
liver cancers [58]. Hbv infections also translate 
into excess mortality risk. estimation from mortality 
registers suggests that Hbv infected patients have 
an excess risk of all-cause mortality and liver-
related mortality [59]. About 46% of this excess 
liver-related mortality is explained by liver cancer. 
Hbv infection is responsible for a mortality rate of 
2.7 and 2.5 persons per 100,000 inhabitants per 
year in spain and france, respectively [60, 61].
the available data suggest there has been a 
reduction in yearly incidence of Hbv, accompanied 
by a decline in prevalence related to the vaccination 
campaigns that have been mounted throughout 
europe (table 6 and 7, page 27) [62, 63]. However, 
a lack of reliable epidemiological data on Hbv is 
one of the biggest obstructions to the development 
of policies for its management. for example, 
surveillance data collected by the european centre 
for disease prevention and control (ecdc) must 
be interpreted with caution because of the absence 
of a standardized definition of Hbv infection. 
despite vaccination and decreased incidence, 
Hbv infection remains a public health issue with 
many patients unaware of their Hbv status. 
those patients are faced with many complications 
including cirrhosis and liver cancer, leading to 
increased mortality rates.
HepaTiTis b
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Country % anti-HbC % Hbsag
belgium 1.3 0.7
czech republic 2.5 0.3
germany 6.0 -
italy 5.6 0.6
luxembourg 2.9 -
romania 20.5 5.6
slovakia 10.5 0.6
finland 2.7 0.2
ireland 1.7 0.1
Netherlands 1.7 0.1
france* 7.0 0.65
*data added from institut de veille sanitaire,  2004 [65]
Fig. 14 – Incidence rates of hepatitis B in EU27 countries in 2005; ECDC 2007.
Caution: there is no of standardized definition of new HBV cases; sometimes reactivations are included.
Table 5 – Age-specific HBV seroprevalence in European countries [64].
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Country author study year 
and population
Case identification incidence rates 
per 100,000
Trends in incidence rates
poland czarkowski [66, 67] 2006; general 
population
mandatory declaration 4.4 stable since 2005 when the 
rate was 4.5
romania pitigoi [68] 2004; general 
population
mandatory declaration 8.5 decreased from 43 in 1989
Country author
study year and 
population
diagnostic 
method
seroprevalence
Trends in 
seroprevalence
belgium Quoilin [48] 2006; general population Hbs antigen testing 
in saliva
0.66% 
france meffre [69] 2004; general population Hbs antigen testing 
in serum
0.65%
greece Zacharakis [63] 2006; general population Hbs antigen testing 
in serum
3.4% decreased from 
5.4% in 1994
greece papaevangelou [70] 1998; children Hbs antigen testing 
in serum
0.6%
italy fabris [71] 2007; general population 
in northern italy
Hbs antigen testing 
in serum
1%
Netherlands baaten [72] 2004; general population 
in Amsterdam
Hbs antigen testing 
in serum
0.4%
romania voiculescu [73] 2009; general population 
se romania
Hbs antigen testing 
in serum
5.6%
spain salleras [74] 2002; general population 
in catalonia
Hbs antigen testing 
in serum
0.7% (0.4-1) decreased from 
1.5% in 1989
Table 7 – Seroprevalence of chronically HBV-infected patients in Europe.
Table 6 – HBV incidence in Europe.
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Hepatitis c is caused by infection with the 
hepatitis c virus (Hcv). Hcv is transmitted through 
percutaneous exposure to infected blood, e.g. 
through intravenous drug use, transfusion [75, 76] 
and medical procedures [77, 78]. About 90% of 
Hcv infection remains asymptomatic. in europe, 
a significant number of persons acquired hepatitis 
c virus in the 1970’s and 1980’s before the virus 
was identified and a diagnostic test was available. 
since then, the transmission of infection has been 
greatly reduced and it is now mainly concentrated 
in intravenous drug users. However the disease has 
a prolonged time-course, individuals developing 
cirrhosis within 20 years [79], and so the disease 
burden of Hcv in europe is at its peak only now.
there is a lack of reliable epidemiological data on 
Hcv in europe [80]. An annual average incidence 
rate of 6.19 per 100,000 inhabitants (95% ci 4.90-
7.48) can be estimated, based on rates reported 
from the european region to the wHo [80]. Available 
literature suggests that the overall prevalence in 
europe, estimated from serum antibodies, varies 
between 0.12% and 3.23% (table 8, page 29). this 
accords with the 0.003 % to 4.5% prevalence rate 
reported by wHo for the wider european region (as 
geographically-defined by wHo) [80]. intravenous 
drug users are particularly exposed to the risk of 
Hcv infection, with prevalence rates of up to 50% 
in cyprus [81], 59.8% (95% ci 50.7-68.3) in france 
[82], 75% for those admitted for opiate detoxification 
in germany and 83.2% in italy [83].
studies on the natural history of the disease show 
that up to 85% of infected patients develop a 
chronic infection, with 10 to 20% progressing to 
cirrhosis [75]. About 7% of cirrhosis patients will 
develop hepatocellular carcinoma (Hcc) [84] and 
Hcv is an important risk factor for this cancer [58]. 
Hcv is the main indication for virus-related liver 
transplantation (fig. 15, page 29). current studies in 
patients diagnosed with hepatitis c show increased 
morbidity, with higher hospital admission rates [85] 
and mortality rates three times higher than that of 
the general population, due to both drug use and 
liver disease [86]. it is estimated that there are 2.5 
Hcv-associated deaths per 100,000 inhabitants in 
france, 95% with cirrhosis and 33% with Hcc at 
death [61]. in spain, the mortality rate due to Hcv 
infection is 11.25 per 100,000 inhabitants [60]. 
cost analysis, including the cost of complications, 
shows that the median lifetime cost for treating 
one patient with dual therapy (pegylated interferon 
and ribavirin) is between eUr 7,517 and eUr 
21,229, depending on the virus genotype [87]. 
in cost effectiveness analyses of new protease 
inhibitors for treating chronic hepatitis c universal 
triple therapy costs an additional Usd 70,100 per 
quality-adjusted life year (QAly) (mild fibrosis) and 
Usd 36,300 QAly (advanced fibrosis) compared 
with standard pegylated interferon plus ribavirin 
therapy [88].
models suggest that Hcv-related morbidity will 
rapidly increase in the short-term. in the UK, 
models based on the natural development of Hcv 
and on epidemiological data suggest that Hcv-
related cirrhosis and death from Hcc are likely to 
increase dramatically in the next decade, reflecting 
the increased incidence of Hcv infection in the early 
1980’s [89]. A recently published model  suggests 
that treatment with pegylated interferon and 
additional effects of triple therapy with a protease 
inhibitor could reduce Hcv genotype 1-related 
cumulative incidence by 17.7% and mortality by 
9.7% between 2012-2021 [90].
Although Hcv transmission has been greatly 
reduced and prevention strategies have been 
effective [91], the issue of patients now chronically 
infected with Hcv needs to be addressed as these 
patients will represent a heavy disease burden in 
the coming years.
HepaTiTis c
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Country author
study year and 
population
Case identification prevalence
Trends in 
prevalence
belgium Quoilin [48] 2007; general population Anti-Hcv testing in saliva 0.12%
france meffre [69] 2004; general population Anti-Hcv testing in serum 0.65%
france delarocque-
Astagneau [91]
2004; adults aged 20-59  Anti-Hcv testing in serum 0.71% decreased from 
1.05% in 1994
italy cozzolongo [92] 2007; southern italian town Anti-Hcv testing in serum 2.6%
italy fabris [71] 2008; nothern italy Anti-Hcv testing in serum 2.6%
Netherlands baaten [72] 2004; general population Anti-Hcv testing in serum 0.6%
romania gheorghe [93] 2008; general population Anti-Hcv testing in serum 3.23%
HBV + HDV 8%
HBV + HCV 4%
HCV 63%
HBV 24%
HBV + HCV + HDV 1%
Fig. 15 – Primary indications for liver transplantation in Europe among patients 
with virus-related liver disease (January 1988 to December 2009).
Table 8 – HCV prevalence in Europe.
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Hepatitis delta virus (Hdv) is a small, defective rNA 
virus. it can infect only an individual who has also 
been infected by Hbv, either after concomitant 
transmission of the two viruses (so called co-
infection), or via a subsequent infection of a Hbv 
infected patient (so-called super-infection) [94]. 
Hdv co-infection may cause a benign, self-limited 
disease. However, it has been consistently shown 
that most patients with Hbv and Hdv co-infection 
develop chronic infection and have more severe liver 
disease [95, 96], more rapid progression to cirrhosis 
[97, 98] and increased hepatic decompensation, 
and death [99] compared with patients who have 
chronic Hbv infection alone.
the highest prevalence is seen in central Africa, 
the Horn of Africa, the Amazon basin, eastern and 
mediterranean europe, the middle east, and parts 
of Asia [100]. However, prevalence rates are also 
high in some eastern european countries. most of 
the cases recorded in other european countries 
are found in populations originating from endemic 
regions. limited data are available for basing an 
estimate of Hdv prevalence in european countries.
Among 16,597 Hiv patients enrolled in eurosidA, 61 
of 422 (14.5%) HbsAg-positive carriers were anti-
Hdv-positive. Hdv predominated in intravenous 
drug users and in southern and/or eastern europe. 
serum Hdv-rNA was detectable in 87% of anti-
Hdv-positive patients [101].
in switzerland the prevalence of Hdv infection in 
1,699 patients with chronic hepatitis b was 5.9% 
[102]. for two decades (1989 to 2008), 1,307 
HbsAg carriers were followed for a mean of 7 ± 6 
years at düsseldorf University hospital. Hepatitis d 
prevalence increased from 4.1% to 6.2% among 
HbsAg carriers during the two decades (p < 0.06). 
the proportion of patients originating from the 
former soviet Union (32.1 vs. 46.2%) and Africa 
(0 vs. 17.9%) increased whereas the proportion 
of patients from southern europe decreased (46.5 
vs.17.9%; p < 0.03). 
estimated survival and complication-free survival 
during 12 years were 72% and 45% in cirrhotic 
patients compared to 100% in non-cirrhotic 
patients (p < 0.008 and p < 0.0001, respectively) 
[103].
Among 737 patients from a large cohort of HbsAg-
positive patients in central italy, 4.2% and 17% of 
italian patients and patients from outside of the 
eU, respectively, had anti-Hdv antibodies [104]. 
the prevalence of Hbv and Hdv in liguria, italy 
(1,572,000 inhabitants), was assessed in a network 
of 12 referral centres for liver diseases. All patients 
with HbsAg followed throughout 2006 were 
included. 445 (71% male) were evaluated, in whom 
the prevalence of Hdv infection was 5.7% [105]. 
in southern italy, 1,336 HbsAg positive subjects 
consecutively observed in 79 italian hospitals were 
evaluated over a 6-month period. the proportion 
of patients co-infected with Hdv was 9.7% [106].
A retrospective analysis of 962 consecutive Hbv-
infected adult patients referred to King’s college 
Hospital in london was performed between january 
1st 2000 and march 31st 2006. excluding non-UK 
residents, the prevalence of anti-Hdv antibodies 
was 7.1%. most Hdv-infected subjects were born 
in regions where Hdv is endemic, for example 
southern or eastern europe (28.1%), Africa (26.8%) 
or the middle-east (7.3%) [107].
HepaTiTis d
percentage of serum Hdv-rNA detected 
among anti-Hdv-positive patients.
87%
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Hepatitis e virus (Hev) is the causative agent 
of an acute form of hepatitis identified in 1983. 
infection in severely immunocompromised patients 
produces a chronic form of the disease. Hepatitis 
e is also known to cause infections in animals, 
particularly, but not exclusively, in pigs. epidemics 
have occurred regularly in many countries across 
south and southeast Asia and in Africa. Although 
hepatitis e has been reported from many european 
countries [108], its incidence in europe is largely 
unknown, and the seroprevalence of Hev infection 
is also unknown for most countries in this region.
three studies investigated the prevalence of 
Hev infection in spain. Anti-Hev antibodies were 
detected in fifty samples (2.17%) of 2,305 serum 
samples taken from the general population (aged 
2-60 years) in madrid [109]. in a representative 
sample of 1,249 healthy children from North-
eastern spain aged between 6 and 15 years; anti-
Hev antibodies were detected in 57 (4.6%) children, 
suggesting that some children are exposed to Hev 
in early childhood [110]. in a community-based 
seroepidemiological survey of Hev infection in 
catalonia, anti-Hev antibodies were detected in 96 
(7.3%) of the 1,280 samples analysed [111]. 
two studies provide estimations of the prevalence 
of Hev infection in switzerland. Among 735 
Hiv-infected patients with unexplained alanine 
aminotransferase elevation the prevalence of 
anti-Hev antibodies was 2.6% [112]. Among 550 
consecutive blood donor samples collected in 
the region of lausanne, anti-Hev antibodies were 
found in 27 (4.9%). the seroprevalence was 5.4% 
(18/332) in men and 4.1% (9/218) in women [113]. 
in southwest france the prevalence of anti-Hev 
antibodies among 529 samples from rural and 
urban blood donors was 16.6%, (19.1% in rural 
donors and 14.2% in urban donors) [114]. in the 
paris area, the prevalence of anti-Hev antibodies 
in blood donors was 3.2% [115]. 
Among 184 patients infected with Hiv in marseille, 
the prevalence of serum anti-Hev antibodies and 
Hev rNA was 4.4% (8/184) and 1.6% (3/184), 
respectively [116].
in italy, 92 workers at risk from zoonoses and 3,511 
controls from the general population of rome and 
rieti were tested for anti-Hev antibodies. the 
prevalence was 2.9% in the general population 
compared with 3.3% among pig breeders. the 
prevalence in subjects recruited in rome and rieti 
was 2.5% and 5.5%, respectively (p = 0.0004) 
[117].
HepaTiTis e
year when Hepatitis e virus (Hev) 
was identified.
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NAfld is defined by the presence of liver fat 
accumulation exceeding 5% of hepatocytes in the 
absence of significant alcohol intake (20 g per day 
for men and 10 g per day for women), viral infection, 
or any other specific aetiology of liver disease. 
NAfld encompasses a histological spectrum 
ranging from simple steatosis (ss) to non-alcoholic 
steatohepatitis (NAsH), which is characterized 
by ss plus necroinflammation. NAsH can have 
different stages of fibrosis ranging from absent 
(stage f0) to cirrhosis (stage f4). ss, NAsH, and 
different fibrosis stages can only be differentiated 
by liver biopsy [118].
more than 50% of adults in the eU 27 countries are 
considered to be overweight or obese. According 
to the oecd, 34.6% of the adult population in the 
eU 27 is overweight and 15.5% is obese (fig. 16, 
page 34). obesity presents greater health risks than 
being overweight. the prevalence of obesity varies 
threefold among eU 27 countries, from less than 
10% in romania, switzerland and italy to over 20% 
in the United Kingdom, ireland, malta and iceland. 
overweight and obesity rates are much lower than 
average in france, italy and switzerland but are 
increasing in these countries. in this context, NAfld 
is highly endemic in europe where it represents a 
major potential threat to public health.
our search retrieved 11 european studies that 
estimated NAfld prevalence (table 9, page 35). 
four were population-based studies: the study 
of Health in pomerania (sHip) [119]; a study in 
the province of barcelona [120]; the dioNysos 
study in italy [121]; and the risc study (a large 
study by the european group for the study of 
insulin resistance on the relationship between 
insulin sensitivity and cardiovascular disease) [122]. 
NAfld was diagnosed by ultrasonography except 
in the risc study where the fatty liver index was 
calculated using an algorithm based on body mass 
index (bmi), waist circumference, triglycerides 
(tg’s), and gamma-glutamyl transpeptidase (ggt), 
giving an accuracy of 0.84 (95% ci 0.81-0.87) in 
detecting fatty liver [122]. 
in the barcelona and dioNysos studies, NAfld 
prevalence was 26%, in the sHip study it was 
30.4% and in the risc study 33% of patients had 
a high probability of having the disease [119-121]. 
A recent romanian study using ultrasonography 
estimated NAfld prevalence to be 20% in a large 
sample of patients hospitalized for internal and 
gastrointestinal diseases [123]. A study in greece 
revealed evidence of NAfld in 31% and of NAsH 
in 40% of autopsied cases of ischaemic heart 
disease or traffic accident death (after exclusion 
of hepatitis b seropositivity or known liver disease) 
[124]. one german [125] and two italian [126, 
127] studies have investigated NAfld prevalence 
in children. A high prevalence (36-44%) of NAfld 
was found in obese children, regardless of the 
manner used to diagnose the disease. NAfld is 
known to be highly correlated with diabetes. two 
major european studies [128, 129] reported NAfld 
prevalence rates of 42.6-69.5% in large samples of 
type 2 diabetic patients.
NoN-AlcoHolic FaTTY liver disease 
(NaFld)
of the adult population in the eU27 is 
overweight according to the oecd.
34.6%
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the presence of NAfld carries an increased 
risk of overall mortality and of mortality related to 
cardiovascular disease (cvd) and liver disease. A 
cohort of 1,804 patients with hospital-diagnosed 
NAfld from the danish National registry of 
patients were followed during 16 years [130]. 
After adjustment for sex, diabetes and cirrhosis 
at the baseline, NAfld-associated age-adjusted 
standardized mortality ratios (smr) were 2.3 (95% 
ci 2.1-2.6) for all causes, 19.7 (95% ci 15.3-
25.0) for hepatobiliary disease, and 2.1 (95% ci 
1.8-2.5) for cvd [130]. in the sHip study [119], 
4,160 subjects were followed during 7 years. the 
odd ratios for all-cause mortality and cv mortality 
of ultrasonographic steatosis and highest ggt 
quintile in men were 1.98 (95% ci 1.21-3.27) and 
2.41 (95% ci 1.05-5.55), respectively. the risk 
was not increased in women. the analyses were 
adjusted for age, waist circumference, alcohol 
consumption, physical activity, educational level, 
civil status, equalized income and functional co-
morbidity index. A cohort of swedish subjects with 
NAfld that had been identified by elevated liver 
enzymes and liver biopsy between 1980 and 1984, 
were assessed for mortality in comparison with 
the general swedish population during a 28 year 
follow-up period [131]. 
the age, sex, and calendar-period adjusted 
mortality ratio was 1.69 (95% ci 1.24-2.25) for 
NAfld compared to the general population, even 
after excluding cirrhotic patients at the baseline. 
cvd, malignancy and liver disease were the top 
three causes of death. in the cremona study on 
incidence and duration of diabetes in italy, >2,000 
middle-aged individuals were followed for 15 years. 
the fatty liver index was significantly associated 
with a higher liver-related mortality in a multi-
adjusted analysis [132].
NAfld already represents an important burden for 
european countries. A german study investigated 
the sHip cohort for the relationship between fatty 
liver disease, self-reported health-care utilization 
and costs. the average annual overall health-care 
costs were significantly higher at baseline and 
at follow-up measurements for individuals with 
evidence of NAfld [133]. for example, controlling 
for comorbid conditions, subjects with sonographic 
fatty liver disease and increased serum alanine 
amino transferase (Alt) levels had 26% higher 
overall health-care costs at 5-year follow-up.
higher over-all health costs at 5 year follow 
up for individuals with sonographic fatty liver 
disease and increased serum Alt.
26%
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Fig. 16 – Obesity rates among populations of European countries; OECD Health data 2008. 
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Country author study year(s) and population Case 
identification
prevalence (of NaFld 
unless otherwise stated)
14 eU countries gastaldelli [122] 2002-2004; 1400 apparently healthy 
subjects between 30 and 60 yr, 44% 
male
fatty liver index* 33%
germany imhof [125] 2002; 378 children and adolescents 
aged 12–20 yr, 49% male
Ultrasonography 
and liver enzymes
2% overall, 36% in obese 
male children
germany Haring [119] 2007; 4160 subjects aged 20-79 yr Ultrasonography 30.4%
greece Zois [124] 2006-2008; post-mortem material 
from 498 patients aged 3-94 yr, 68% 
male
Histology 31%, NAfld and 40% NAsH 
italy bedogni [121] 2001-2002; 659 subjects aged 18 to 
75 yr, 58% male
Ultrasonography 26%
italy caserta [126] 2007-2008; 676 adolescents aged 
11–13 yr, 49.5% male
Ultrasonography 12.5% (95% ci 10.0-15.3)
italy sartorio [127] 2006; 268 obese children aged 6-20 
yr, 44% male
Ultrasonography 44%
italy targher [128] 2005-2006; 2,839 type 2 diabetic 
outpatients aged 40-86 yr, 55% male
 
Ultrasonography 69.5% (95% ci 68.5-70.5)
romania radu [123] 2006-2007; 3,005 inpatients, mean 
age 54 yr, 44% male
Ultrasonography 20%
spain caballeria [134] 2007-2008; 773 individuals aged 15-
85 yr, 42% male
Ultrasonography 25.8% overall, 33.4% in men 
and 20.3% in women 
UK williamson [129] 2006-2007; 939 type 2 diabetic 
patients aged 60-74 yr, 52% male
Ultrasonography 42.6% 
* fatty liver index is based on bmi, waist circumference, triglycerides, and gamma-glutamyl-transferase ggt.
Table 9 – European studies assessing the prevalence of NAFLD.
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drug-induced liver injury (dili) is a major problem 
for affected patients and health care providers. it is 
also a strong consideration in differential diagnosis 
when abnormal liver-related chemistries are 
identified in persons with minimal or no symptoms. 
there is presently no specific diagnostic test for dili, 
or a means of confidently singling out an implicated 
drug among potentially many. consequently, it 
is an important challenge for physicians, health 
authorities and pharmaceutical companies [135]. 
the overall frequency of hepatotoxicity for all drugs 
has not decreased in the last 15 years despite 
improvements in toxicological studies and in the 
safety analyses of clinical trials. furthermore, the 
early detection of drug hepatotoxicity remains very 
difficult [135]. these difficulties are partly related 
to the discrepancy between preclinical studies 
in animal species which exhibit limited negative 
predictive values and a number of cases of liver 
injury in humans, whereas no signal has been 
detected in animal models. 
the difficulty of liver injury detection is also related 
to the diversity of liver injury expression. indeed, 
all liver cells can be affected by drugs [135]. the 
types of lesions may also vary in their clinico-
pathological manifestations, according to the 
mechanism of hepatotoxicity, the drug itself, 
details of the treatment course (dosage, duration 
of treatment), and the susceptibility of the person 
taking the agent. it is noteworthy that besides 
the large number of “classical” drugs (more than 
1,200) reported to exhibit potential hepatotoxicity 
[136], other agents should also be taken into 
consideration. these include the excipients [137] 
present in drug formulations, herbal medicines 
which are increasingly consumed and often not 
disclosed [138-140], and recreational and illegal 
compounds [141, 142]. these general aspects are 
particularly well illustrated by psychotropic agents. 
A large proportion of drug hepatotoxicity occurs as an 
idiosyncratic event (dili), so that its prevalence and 
incidence is still only partially known despite recent 
improvements [135, 143]. A notable exception is 
accidental or suicidal paracetamol intoxication, 
which shows a dose-related liver toxicity, particularly 
when in combination with alcohol. the majority 
of data are provided by retrospective studies of 
databases from pharmacovigilance centres and/
or pharmaceutical companies. what we currently 
know about the burden of dili may only represent 
the ‘tip of the iceberg’ [135].
few epidemiological data on dili in europe are 
available. in an analysis of a swedish database of 
1,664 cases seen for the first time between 1995-
2005 dili with at least a possible causal relationship 
was found in 77 cases (6.6%). 38 cases (3.3%) 
were referred for evaluation to the out-patient clinic 
whereas 3% had a follow-up after hospitalization 
for dili [144].
in the UK the incidence of dili in the general 
population has been estimated to be 2.4 cases 
per 100,000 person years (based on the UK-based 
general practice research database) [145].
A recent prospective study performed over three 
years in france in an area comprising 81,000 
inhabitants showed an incidence of 14 cases per 
100,000 persons and corresponded to a number 
of events 16 times higher than that collected by 
pharmacovigilance centres [146]. 
retrospective studies suggest that drugs may have 
caused around 10-20% of all cases of fulminant 
and subfulminant hepatitis [147, 148]. in a french 
study 5.5% of liver transplantations were related 
to drug-induced acute liver failure, of which 36.4% 
were due to paracetamol (acetaminophen) intake 
[149]. of the 674 dili references new to the 
HepAtoX database between september 2010 and 
August 2011, 16% concerned neuropsychiatric 
compounds, including carbamazepine, phenytoin 
and valproic acid. these data are consistent with 
data collected in the vigibasetm [150].
drUg iNdUCed liver iNjUries (dili)
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Hereditary haemochromatosis is a disease of iron 
regulation that results in excessive iron absorption, 
and ultimately, in iron overload.  it is associated 
with an increased incidence of hepatic cirrhosis, 
diabetes mellitus, cardiomyopathy, and other 
clinical complications. it is one of the few genetic 
diseases for which a simple and effective therapy 
exists; the removal of iron by phlebotomy improves 
survival in symptomatic persons [151, 152]. when 
phlebotomy is begun prior to the development of 
cirrhosis or diabetes, affected people appear to 
have a normal life expectancy [153]. symptoms of 
haemochromatosis are nonspecific, have a gradual 
onset and mimic other common disorders. As a 
result, they may be attributed to other causes, and 
diagnosis is often delayed.
temporal trends in the diagnosis of 
haemochromatosis have been studied using 
inpatient and day-case admissions in england 
and mortality statistics in england and wales. 
in england during 1989/1990 to 2002/2003, 
there was an increase in both genders in age-
standardized in-patient admission rates attributable 
to haemochromatosis (figure 17, page 38). in men, 
the admission rate rose by 269%, from 0.64 to 
2.36 per 100,000. in women, the admission rates 
were lower, but the absolute increase was similar 
at 290% (0.21 to 0.81 per 100,000) (fig. 17a). 
day-case admissions rose even more markedly 
during the time period studied, the age-
standardized admission rate for men rising 11-fold 
from 2.78 to 34.9 per 100,000, and for women 
rising 19-fold from 0.58 to 11.67 per 100,000 (fig. 
17b) [154].
Haemochromatosis is a result of mutations in 
the Hfe gene which encodes for the human 
haemochromatosis protein. these mutations can 
be used to assess prevalence. in two population-
based studies conducted in northern Norway, 
a total of 6,297 women and 5,012 men were 
analysed for serum ferritin (s-ferritin) and transferrin 
saturation. those with levels above the reference 
limits in two separate blood samples (74 women 
and 94 men in sør-varanger and 253 women and 
285 men in tromsø) were tested for three different 
Hfe mutations: c282y, H63d and s65. in sør-
varanger, the prevalence of the c282y/c282y 
mutation among men and women was 0.22% in 
both genders. in the tromsø survey, the prevalence 
among men and women was 0.12% and 0.05%, 
respectively [155]. the allelic frequencies of 
c282y and H63d have also been estimated in 
a sample of 200 individuals evenly-distributed 
over North-eastern romania. they were either 
healthy blood-donors or were persons who 
presented as ambulatory or hospital patients with 
various diagnoses, excluding hepatic diseases, 
heart diseases or diabetes. the calculated 
allelic frequency of the two mutant alleles in this 
population sample was 1.75% (95% ci 0.7-3.7) for 
c282y and 13.25% (95% ci 10.4-16.5) for H63d 
[156].
HaeMOCHrOMaTOsis
the increase in female in-patient admission 
rates attributable to haemochromatosis between 
1989/1990 and 2002/2003 in the UK.
29 fold
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Fig. 17 – Hospital admissions attributed to haemochromatosis in England from 1989/1990 to 2002/2003. 
(a) Age-standardized in-patient admission rate per 100,000 per year. 
(b) Age-standardized day-case admission rate per 100,000 per year [154].
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A registry of patients with genetic haemochromatosis 
was established in the south of france, together with 
a regional health network to ensure the inclusion of 
all diagnosed patients. patients were included in 
the registry over a 6-year period from 2002 to 2008 
if they were homozygous for the c282y mutation 
and were classified in stages 2-4  of the french 
National Authority for Health haemochromatosis 
classification (2 = biological iron overload, 3 and 
4 = increasingly severe clinical manifestations of 
iron overload). in total, 352 symptomatic c282y 
homozygotes were identified, giving a total 
prevalence of 1.83 per 10,000 (95% ci 1.63-2.02) 
in subjects over 20 years old and 2.40 per 10,000 
(95% ci 2.15-2.65) among subjects of european 
descent. Among europeans, the total calculated 
penetrances were 15.8% for those in stage 2 or 
higher, 12.1% for those in stage 3 or 4, and 2.9% 
for those in stage 4 [157].
A danish epidemiological population survey 
assessed the penetrance of the most frequent 
Hfe gene variants in ethnic danish men. A 
cohort of 6,020 men aged 30-53 years was 
screened for c282y, H63d and s65c variants by 
restriction fragment length polymorphism analysis 
(rflp). subsequently, iron-status markers (serum 
transferrin saturation and serum ferritin) were 
analysed in 1,452 men. the c282y allele was 
present in 5.6%, H63d in 12.8%, and s65c in 1.8% 
of the men. Among untreated c282y homozygotes 
with available iron-status markers (n = 21), 89% had 
elevated transferrin saturation, 94% had elevated 
ferritin, and 88% had elevation of both iron-status 
markers; seven out of 16 (44%) had ferritin values 
>800 μg/l [158].
the prevalence of c282y homozygotes per 
10,000 of a southern french population.
1.83%
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there is no single specific test for diagnosis 
of autoimmune hepatitis (AiH). However, sero-
immunological and molecular biological tests 
contribute to discrimination of AiH from other 
aetiologies of chronic hepatitis, in particular from 
chronic viral infection, the most common cause of 
chronic hepatitis. diagnosis relies on a combination 
of indicative features of AiH and on the exclusion 
of other causes of chronic liver diseases. the 
clinical appearance ranges from an absence of 
symptoms, to a severe or fulminant presentation 
and it responds to immunosuppressive treatment 
in most cases. An association with extrahepatic 
autoimmune diseases is frequent.
Unfortunately, very little data is available on the 
incidence and prevalence of AiH. much of the 
information regarding AiH comes from studies 
of idiopathic chronic active hepatitis. prior to the 
introduction of the ‘Autoimmune Hepatitis: revised 
scoring system’ in 1999, there was no standardized 
way of evaluating patients with suspected AiH 
and, as a result, the studies included somewhat 
heterogeneous patient populations. Nevertheless, 
based on limited epidemiological data, the 
prevalence of AiH is estimated to range from 
5-20 cases per 100,000 among the caucasian 
population in western europe. it is estimated to 
account for up to about 20% of cases of chronic 
hepatitis among the caucasian population of North 
America and western europe [159].
three recent population-based studies in european 
populations have estimated incidence and 
prevalence of AiH (table 10, below). in a Norwegian 
population, a mean annual incidence of 1.9 cases of 
AiH per 100,000 person-years and a prevalence of 
16.9 per 100,000 of the population were observed 
[160]. A spanish study drew on all patients who 
were newly-diagnosed with AiH in 2003 in the 
gastroenterology departments of eight acute-care 
reference hospitals in the province of valencia, 
covering ~1.8 million inhabitants over 14 years of 
age. the AiH incidence rate was 1.07 per 100,000 
inhabitants overall, with 1.96 and 0.12 cases per 
100,000 for females and males, respectively [161]. 
in a swedish study, the incidence of AiH was 0.85 
per 100,000 inhabitants (95% ci 0.69-1.01), its 
prevalence was 10.7 per 100,000 (95% ci 8.8-
13.1), 76% of cases were female and 30% of 
patients with AiH had liver cirrhosis [162].
A german study has shown that AiH is commonly 
associated with liver cirrhosis but not with Hcc. 
32% of a cohort of 278 patients with AiH were 
diagnosed with liver cirrhosis. the average follow-
up was 4.8 years per patient and, during this 
period, none of the patients developed Hcc. this 
study should be interpreted with caution because 
of its lack of power but the incidence of Hcc 
associated with AiH-induced cirrhosis appears 
to be significantly lower than that associated with 
other causes of liver cirrhosis, such as chronic viral 
hepatitis, alcohol or haemochromatosis [163].
aUTOiMMUNe HepAtitis
Country author study year(s) and population incidence per 
100,000 person-
years
prevalence 
per 100,000 
inhabitants
Norway boberg [160] 1986-1995; Aker University Hospital registry 1.9 16.9 
spain primo [161] 2003; valencia hospitals’ registries 1.07
sweden werner [162] the swedish internal medicine liver club registry 0.85 10.7 
Table 10 – European studies assessing the prevalence and incidence of autoimmune hepatitis.
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pbc is an autoimmune liver disease characterised 
by the presence in serum of highly-specific anti-
mitochondrial antibodies (AmAs) and progressive 
destruction of intrahepatic bile ducts, resulting 
in chronic cholestasis, portal inflammation and 
fibrosis that can lead to cirrhosis and, ultimately, 
to liver failure. the disease predominantly affects 
women, who are diagnosed typically in their fifth 
and sixth decade, although younger patients have 
been described, including children (albeit rarely).
data on the incidence and prevalence of pbc have 
generally been obtained passively and so might not 
indicate true rates in the general population. indeed, 
a population-based approach to the detection 
of cases has little feasibility for pbc because of 
its rarity. regional differences in incidence and 
prevalence of pbc are probably secondary to 
variability in factors such as diagnostic criteria, 
case-finding methods, doctors’ awareness, and 
quality of health-care systems.
on the basis of case-finding studies, the disease has 
been found to be most frequent in northern europe 
and North America. the highest prevalence and 
incidence rates have been reported in scandinavia, 
great britain and the northern midwest region of the 
UsA. An exception to this pattern is the high rate 
found in the spanish area of sabadell [164]. some 
researchers suggest that the incidence of pbc is 
growing. in the UK, incidence rates rose from 0.58 
to 2.05 cases per 100,000 population per year 
in sheffield from 1980-1999 [165] and from 1.1 
to 3.2 cases per 100,000 population per year in 
Newcastle-upon-tyne from 1976-1994 [166, 167]. 
this increase was paralleled by rise of prevalence 
to more than 20 cases per 100,000 in the mid-
to-late 1990’s. in finland, the age-standardized 
prevalence of pbc increased between 1988 and 
1999 from 10.3 (95% ci 97-110) to 18.0 (95% ci 
172-189) per 100,000 inhabitants.
over the same period, incidence increased from 12 
(95% ci 10-14) to 17 (95% ci 15-20) per million 
inhabitants per year. the annual average increases 
in prevalence and incidence were 5.1% (95% ci 
4.2-5.9%, p<0.0001) and 3.5% (95% ci 0.9%-
6.0%, p=0.008), respectively [168]. it remains to 
be established whether these changes are due 
to rising disease incidence or reflect improved 
detection of mild asymptomatic cases or of slowly 
progressing disease.
the progression of pbc in patients is extremely 
variable. studies of asymptomatic patients suggest 
that their survival is reduced when compared with an 
age- and gender-matched population. in a canadian 
study, authors retrospectively reviewed all patients 
with abnormal liver biochemical tests, positive AmA 
tests and liver-biopsy-compatible pbc. Among the 
91 patients concerned, the standardized mortality 
ratio was 2.87 (95% ci 1.38-4.63) [169]. patients 
may, on occasion, present de novo with a variceal 
haemorrhage. this may be caused by non-cirrhotic 
portal hypertension [170] or may be secondary to 
cirrhosis. complications of variceal haemorrhage 
are not predicted by standard prognostic indices. 
once pbc has progressed to frank cirrhosis, liver 
complications do not differ much from those seen 
in cases of cirrhosis associated with other causes. 
complications of portal hypertension (i.e. ascites 
and hepatic encephalopathy) are typical in end-
stage pbc. the occurrence of hepatocellular 
carcinoma in individuals with pbc is similar to 
that associated with other forms of cirrhosis and 
warrants surveillance in patients at advanced 
stages of disease [171].
primAry biliarY CirrHOsis (pbC)
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psc is a chronic cholestatic liver disease of an 
unknown aetiology that is characterized by chronic 
inflammation, destruction and fibrosis of the 
intrahepatic and/or extrahepatic biliary tree. this 
aberrant inflammatory response may ultimately 
lead to cirrhosis, end-stage liver disease, and the 
need for liver transplantation [172].
three recent european studies have investigated 
psc incidence. in a large population-based study 
in sweden an incidence of 1.22 (95% ci 1.06-1.40) 
per 100,000 person-years was observed between 
1992 and 2005 [173]. in a british population-based 
study of more than five million person-years between 
1984 and 2003, psc incidence was 0.91 (95% ci 
0.68-1.21) per 100,000 person-years [174]. in a 
second UK study based on the general practice 
research database and conducted between 1991 
and 2001, the incidence of psc was 0.41 (95% ci 
0.34-0.48) [175]. in this study, the risk of death or 
liver transplantation was more than tripled for psc 
patients and the risk of all malignancy was more 
than doubled. However this last study should be 
interpreted with caution because the gprd is not 
population-based and the code for psc was not 
validated.
it should also be noted that psc is one of the 
principal aetiologies of liver transplantation in cases 
of cholestatic disease (fig. 18, below).
primAry sClerOsiNg CHOlaNgiTis 
(psC)
Fig. 18 – Primary indications for liver transplantation in Europe among patients with cholestatic diseases, 
January 1988 to December 2009.
Other non congenital biliary diseases 5%
Other congenital biliary diseases 10%
Primary sclerosing cholangitis 44%
Biliary atresia 41%
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table 11 on page 44 and table 12 on page 
45 summarise the currently-available data on 
the incidence and prevalence of the main liver 
diseases in europe. country comparisons should 
be carried out with caution as these data are based 
on numerous different sources, sometimes with 
different epidemiological definitions. However, it is 
clear that data in the literature is scarce and that 
more efforts should be made to fully understand 
the extent of the burden of liver disease in europe.
table 13 on page 46 and table 14 on page 47 
compare the epidemiological data for some of the 
liver diseases reviewed here with data available 
for other diseases. table 13 shows the mortality 
caused by primary liver cancer and by cirrhosis 
in comparison with that caused by colon cancer, 
breast cancer, chronic obstructive respiratory 
diseases and nephritis diseases. All data are derived 
from the wHo database to enhance comparability. 
table 13 clearly demonstrates that both primary 
liver cancer and cirrhosis cause a non-negligible 
number of deaths compared to other diseases. 
finally, table 14 compares available prevalence 
data for Hbv and Hcv with the prevalence of Hiv 
in adults, showing that fewer people in europe are 
living with Hiv than are living with Hbv or Hcv.
   
CONClUsiON
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Cirrhosis primary liver cancer Hepatitis b
Austria - 2.7 – 7.9 7
belgium - 1.4 – 3.8 5.3
bulgaria - 2.2 – 5.6 -
czech republic - 2.5 – 6.4 3.5
cyprus - - 0.8
denmark 11.2 – 26.5 1.9 – 6.3 0.5
estonia - 1.5 – 3.5 5.8
finland - 2.2 – 5.2 -
france - 0.8 – 13.8 0.2
germany - 2.2 – 6.2 1.4
greece - 13.2 - 4.3 0.8
Hungary - 1.8 – 6.1 1.2
iceland - - 11.2
ireland - 1.5 – 3.4 1.8
italy - 4.4 – 21.1 1.8
latvia - - 7.4
lithuania - 1.4 – 4.1 4.1
luxembourg - 3.8 – 9.8 1.1
Netherlands - 0.8 – 2.4 1.7
Norway - - 3.2
malta - - 3
poland - 1.7 – 3.2 1.2 - 4.4
portugal - 1.2 – 3.5 0.8
romania - - 8.5
slovakia - 2.3 – 5.8 2.3
slovenia - 2.3 – 7.7 0.9
spain - 9.6 – 2.5 1.5
sweden 12.9 – 17.7 1.8 – 3.3 2.4
UK 14.55 - 26 1.9 – 4.2 0.7
† for sources see related sections of the report
Hcv incidence data are available from the ecdc, but this is subject to caution and it is not included here
this table summarises the data available from the previous sections and, given the range when multiple sources
are available, it cannot be used for comparison.
Table 11 – Incidence of liver diseases per 100,000 inhabitants per year in Europe (where data is available) †.
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Cirrhosis Hepatitis b Hepatitis C NaFld
Austria - - - -
belgium - 0.66 – 0.7 0.12 -
bulgaria - - - -
czech republic - 0.3 - -
cyprus - - - -
denmark 0.07 – 0.13 - - -
estonia - - - -
finland - 0.2 - -
france 0.2 -0.5 0.65 0.65 – 0.71 -
germany - - - 2
greece - 0.6 – 3.4 - 31 – 40
Hungary - - - -
iceland - - - -
ireland - 0.1 - -
italy - 0.6 – 1.0 2.6 10 – 26
latvia - - - -
lithuania - - - -
luxembourg - 0.6 - -
Netherlands - 0.1 – 0.4 0.6 -
Norway - - - -
malta - - - -
poland - - - -
portugal - - - -
romania - 5.6 3.2 20
slovakia - 0.6 - -
slovenia - - - -
spain - 0.4 – 1.0 - 25.8
sweden - - - -
UK 0.076 - - 46.2
† for sources see related sections of the report
this table summarises the data available from the previous sections and, given the range when multiple sources are 
available, it cannot be used for comparison.
Table 12 – Prevalence (%) of liver diseases in Europe (where data is available) †
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Austria 8.3 2,488 1,642 2,425 913 782 1,393
belgium 10.6 3,237 2,449 4,635 1,294 671 1,130
bulgaria 7.6 2,719 1,428 1,676 1,351 825 1,794
czech republic 10.3 4,317 1,862 2,082 1,059 792 2,043
denmark 5.5 2,355 1,439 3,037 543 314 889
estonia 1.3 426 246 222 109 90 373
finland 5.3 1,120 859 1,045 285 397 1,236
france 62.0 20,552 13,950 8,325 7,227 8,024 8,014
germany 82.3 30,992 19,711 24,130 11,789 6,895 15,683
greece 11.1 2,568 2,196 2,089 1,964 1,605 813
Hungary 10.0 4,940 2,222 4,377 565 758 4,870
ireland 4.4 1,039 806 1,248 392 199 287
italy 59.6 20,269 13,222 21,527 8,744 9,753 8,165
latvia 2.3 731 478 271 259 129 465
lithuania 3.3 976 629 805 234 155 1,379
luxembourg 0.5 134 82 113 36 35 73
Netherlands 16.5 5,423 3,764 6,359 1,605 647 852
Norway 4.8 1,762 710 2,033 581 170 215
poland 38.1 12,441 6,408 8,261 4,944 2,137 8,008
portugal 10.7 4,278 1,896 2,690 2,191 893 1,537
romania 21.4 5,359 3,225 5,392 2,200 2,653 10,226
slovakia 5.4 1,960 823 675 650 379 1,513
slovenia 2.0 788 462 399 150 191 629
spain 44.5 15,343 6,711 13,843 7,085 4,580 4,694
sweden 9.2 2,937 1,694 2,649 794 604 650
United Kingdom 61.2 18,951 14,343 29,069 4,804 3,470 7,767
TOTal 498.3 168,107 103,255 149,377 61,767 47,147 84,697
Table 13 – Inter-country comparison of the number of deaths associated with selected diseases compared to liver 
diseases based on death certificates (age-standardized); WHO, 2008.
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Hepatitis b † Hepatitis C † Hiv (95% Ci) *
Austria - - 0.3  (0.2 - 0.4)
belgium 0.66 – 0.7 0.12 0.2  (0.2 - 0.3)
bulgaria - - 0.1  (0.1 - 0.1)
czech republic 0.3 - -
cyprus - - <0.1  (<0.1 - <0.1)
denmark - - 0.2  (0.1 - 0.2)
estonia - - 1.2  (1.0 - 1.5)
finland 0.2 - 0.1  (0.1 - 0.1)
france 0.65 0.65 – 0.71 0.4  (0.3 - 0.5)
germany - - 0.1  (0.1 - 0.2)
greece 0.6 – 3.4 - 0.1  (0.1 - 0.2)
Hungary - - <0.1  (<0.1 - 0.1)
iceland - - 0.3  (0.2 - 0.4)
ireland 0.1 - 0.2  (0.2 - 0.3)
italy 0.6 – 1.0 2.6 0.3  (0.2 - 0.3)
latvia - - 0.7  (0.5 - 0.9)
lithuania - - 0.1  (<0.1 - 0.1)
luxembourg 0.6 - 0.3  (0.2 - 0.4)
Netherlands 0.1 – 0.4 0.6 0.1  (0.1 - 0.1)
Norway - - 0.2  (0.1 - 0.3)
malta - - 0.1  (0.1 - 0.2)
poland - - 0.1  (0.1 - 0.1)
portugal - - 0.6  (0.4 - 0.7)
romania 5.6 3.2 0.1  (0.1 - 0.1)
slovakia 0.6 - <0.1  (<0.1 - <0.1)
slovenia - - <0.1  (<0.1 - 0.1)
spain 0.4 – 1.0 - 0.4  (0.3 - 0.4)
sweden - - 0.1  (0.1 - 0.2)
UK - - 0.2  (0.2 - 0.3)
* source: wHo, 2008 (prevalence is given with 95% confidence interval)
† for sources see related sections of the report. A range is given when multiple sources are available.
Table 14 – Inter-country comparison of the prevalence of HBV, HCV and HIV.
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